Daiichi Sankyo admits supply problem with flu vaccine; gains approval for silodosin in China

23 September 2011

Japanese drug major Daiichi Sankyo (TYO: 4568) announced this week that its domestic subsidiary, Kitasato Daiichi Sankyo Vaccine, will be unable to supply around 2,360,000 doses out of a planned total of about 4,780,000 Influenza HA vaccine doses for the upcoming flu season.

This is because some batches did not meet quality standards. The remaining 2,420,000 doses are undergoing quality tests and will be shipped only after they match standards. The company intends to disclose new supply plans after receiving the results of quality specification test.

Receives approval for silodosin to treat dysuria in China

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK